Evidence map›Paper›PMID 40865000›Full record

ArticleJournal of proteome research2025

Proteomic Landscapes of 3D and 2D Models of High-Grade Serous Ovarian Carcinoma: Implications for Carboplatin Response.

Jimmy Maillard, Theodoros I Roumeliotis, Ekta Paranjape, Lisa Pickard, Alvaro Ingles R Garces, Jyoti S Choudhary, Udai Banerji

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jimmy MaillardClinical Pharmacology Adaptive Therapy group, Division of Clinical Studies and Division of Cancer Therapeutics, Institute of Cancer Research, London SM2 5NG, United Kingdom.
Theodoros I RoumeliotisFunctional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London SW3 6JB, United Kingdom.ORCID 0000-0002-3354-5643
Ekta ParanjapeClinical Pharmacology Adaptive Therapy group, Division of Clinical Studies and Division of Cancer Therapeutics, Institute of Cancer Research, London SM2 5NG, United Kingdom.
Lisa PickardClinical Pharmacology Adaptive Therapy group, Division of Clinical Studies and Division of Cancer Therapeutics, Institute of Cancer Research, London SM2 5NG, United Kingdom.
Alvaro Ingles R GarcesClinical Pharmacology Adaptive Therapy group, Division of Clinical Studies and Division of Cancer Therapeutics, Institute of Cancer Research, London SM2 5NG, United Kingdom.ORCID 0000-0002-0073-4237
Jyoti S ChoudharyFunctional Proteomics Group, Chester Beatty Laboratories, The Institute of Cancer Research, London SW3 6JB, United Kingdom.
Udai BanerjiClinical Pharmacology Adaptive Therapy group, Division of Clinical Studies and Division of Cancer Therapeutics, Institute of Cancer Research, London SM2 5NG, United Kingdom.ORCID 0000-0003-1503-3123

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-grade serous ovarian carcinoma (HGSOC) is the most common form of ovarian cancer, and finding new treatments remains an unmet need. While drug discovery is typically performed in two-dimensional (2D) monolayers, three-dimensional (3D) culture systems better mimic the in vivo conditions. However, a comprehensive comparison of 3D versus 2D ovarian cancer models is lacking. Here, we quantitatively compared the whole cell proteomic signatures of four ovarian cell lines─PEO1, PEO4, UWB1.289, and UWB1.289+BRCA1─with different status of BRCA genes grown in 2D and 3D. Using isobaric labeling proteomics, we quantified 6404 proteins and identified 371 significantly and commonly altered proteins between 2D and 3D. Proteins upregulated in 3D were enriched for transmembrane transport and NADH:ubiquinone oxidoreductase complex I, while energy metabolism and cell growth pathways also showed dimensionality-dependent changes. Notably, membrane-associated proteins were downregulated in spheroids, particularly EGFR in PEO1. Furthermore, the 3D culture modulated the response to carboplatin, with an increased expression of drug resistance-associated proteins, including NDUF family members in all spheroid models. These findings underscore how culture dimensionality influences both the molecular landscape and the chemotherapeutic response of HGSOC cells and highlights candidate targets for overcoming carboplatin resistance.

Indexed as

CarboplatinCystadenocarcinoma, SerousOvarian NeoplasmsProteomeProteomicsAntineoplastic AgentsCell Culture TechniquesCell Line, TumorDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansSpheroids, CellularAntineoplastic AgentsCarboplatinProteome2D cell culture3D cell cultureovarian cancerwhole cell proteomics

Identifiers

PMID40865000
PMCPMC12501941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.